GcMAF activates macrophages by binding to a receptor on the cells, stimulating them to attack cancer tumors and other pathogens. It also generates superoxide radicals and has anti-angiogenic and antitumor effects.
The new second generation GcMAF developed by Saisei Mirai in collaboration with Dr Hitoshi Hori and Dr Yoshihiro Uto at Tokushima University has higher concentration and stability, as well as superior macrophage phagocytic effectiveness.
What is Gcmaf?
GcMAF is a serum glycoprotein that is naturally produced in the body during a response to viral infection. It has been shown to activate macrophages and exhibit a wide range of remarkable biological activities. GcMAF activation causes superoxide production and phagocytic activity in the cytoplasm of cancer cells, and it directly inhibits proliferation and migration of human prostate cancer cells. It also has anti-angiogenic properties and directly kills cancer cells in vivo.
Gc MAF (second generation) is produced using a new method that results in 10-20 times more concentrated and effective GcMAF and is resistant to oxidation. The product is safe and has not been associated with any adverse side effects in the majority of patients.
GcMAF treatment courses typically last 6 months and are administered 2 times a week. Patients should have blood 25 hydroxy-vitamin D and calcium levels tested regularly. If these are below normal, vitamin D3 doses may need to be adjusted.
How is Gcmaf made?
GcMAF is a serum glycoprotein produced when the sialidase and cegalactosidase enzymes of activated T-cells and B-cells modify Gc protein (also known as vitamin D binding protein). It is then purified by vitamin D affinity chromatography.
Gc MAF stimulates macrophages, a type of white blood cell that engulfs and digests cellular debris, foreign substances, and pathogens. It also activates natural killer cells, which can kill cancer cells. In addition to its macrophage activation properties, GcMAF-RF has been shown to inhibit tumor growth and spread in in vitro models of human prostate and breast cancer cells.
A repeated experiment showed that GcMAF-RF induces the maturation of dendritic cells, a type of antigen-presenting cell, and enhances their functional ability to bind and internalize exogenous antigens. This was comparable to the effect of LPS, a standard inducer of dendritic cell maturation. The activity of our second generation GcMAF remains stable at room temperature for up to 2 weeks and for up to 1 year refrigerated (2-8 degC). The concentration of Gc MAF can vary between individuals, just as lymphocytes or natural killer cells can differ in number from one person to the next.
Can Gcmaf help with cancer?
GcMAF capsule is able to activate macrophages in cancerous cells and destroy them. It can also help to block the spread of cancerous tumours. This is a treatment that can be used alongside other cancer treatments such as chemotherapy, radiation or surgery.
It can also be used with other immune-boosting therapies such as Sonodynamic Therapy (SDT), Photodynamic Therapy (PDT), Maitake Extract, Coley Vaccine and Alpha-Lipoic Acid to improve their effectiveness. GcMAF can be taken orally but is more effective injected as it acts locally on the tumour and metastases.
We offer second-generation GcMAF that is manufactured in our sterile Saisei Mirai cell processing centre from healthy human serum which is carefully screened. This GcMAF is 10-20 times more concentrated and much more stable because it is resistant to oxidation. See Tests for more details. We recommend a minimum course of 6 months (2 times weekly administration). However, each patient is different and additional courses can be required depending on the results.
Is Gcmaf safe?
GcMAF has been clinically demonstrated to be largely free of side effects in the great majority of patients. Low grade fever and eczema have been reported in some cases but are short-term reactions that are significantly less than occur with many other immunotherapies.
We use High-Dose second-generation GcMAF made using a patent pending process which is 10-20 times more concentrated, more effective and much more stable against oxidation than older first-generation GcMAF products currently available. The activity of our GcMAF can be sustained at room temperature for up to 2 weeks without any loss in activity.
We recommend the administration of GcMAF by subcutaneous (SC) or intramuscular injection twice weekly. This can be easily done at home with a size 26G x 1/2′′ (or 27G) needle and a 2.5 ml syringe. We also offer Oral Colostrum MAF which can be taken by mouth daily. GcMAF works especially well in combination with other therapies that don’t reduce immune function such as Sonodynamic Therapy or Photodynamic Therapy, Maitake Extract, Coley Vaccine, Vitamin D3, low dose naltrexone and others.